Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ALNA

Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis

Allena Pharmaceuticals logo

About Allena Pharmaceuticals Stock (NASDAQ:ALNA)

Key Stats

Today's Range
N/A
50-Day Range
$0.02
$0.16
52-Week Range
N/A
Volume
96,558 shs
Average Volume
15.69 million shs
Market Capitalization
$37,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Stock News Headlines

Allena Pharmaceuticals Inc ALNAQ Stock Quote
Allena Pharmaceuticals Inc (ALNAQ)
When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
San Francisco Pharmaceuticals News
ALNA.O
See More Headlines

ALNA Stock Analysis - Frequently Asked Questions

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) issued its earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06.

Allena Pharmaceuticals (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allena Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Zomedica (ZOM).

Company Calendar

Last Earnings
3/31/2022
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALNA
Employees
35
Year Founded
N/A

Profitability

Net Income
$-48,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.23 per share

Miscellaneous

Free Float
117,566,000
Market Cap
$37,000.00
Optionable
Not Optionable
Beta
1.13
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:ALNA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners